In the phase III AVEREL trial (NCT00391092), locally recurrent or metastatic HER2 + breast cancer patients treated with bevacizumab in conjunction with trastuzumab and docetaxel did not show significant improvement in progression-free survival [118]. Here, ERBB2 is linked to breast cancer.